Ensign Peak Advisors
PCVX icon

Ensign Peak Advisors’s Vaxcyte PCVX Stock Holding History

Ensign Peak Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2M Sell
381,686
-64,217
-14% -$3.49M 0.04% 301
2026
Q1 		$25.9M Sell
445,903
-81,785
-15% -$4.44M 0.05% 264
2025
Q4 		$24.3M Sell
527,688
-1,165
-0.2% -$52.1K 0.04% 267
2025
Q3 		$19M Sell
528,853
-3,350
-0.6% -$111K 0.03% 315
2025
Q2 		$17.3M Sell
532,203
-211,957
-28% -$6.95M 0.03% 342
2025
Q1 		$28.1M Buy
744,160
+158,032
+27% +$12.6M 0.05% 253
2024
Q4 		$48M Buy
586,128
+39,293
+7% +$3.9M 0.09% 195
2024
Q3 		$62.5M Buy
546,835
+84,153
+18% +$7.58M 0.11% 160
2024
Q2 		$34.9M Sell
462,682
-13,018
-3% -$886K 0.06% 215
2024
Q1 		$32.5M Buy
475,700
+114,569
+32% +$7.93M 0.06% 238
2023
Q4 		$22.7M Buy
361,131
+85,345
+31% +$4.43M 0.04% 282
2023
Q3 		$14.1M Hold
275,786
– – 0.03% 321
2023
Q2 		$13.8M Buy
275,786
+26,900
+11% +$1.28M 0.03% 349
2023
Q1 		$9.33M Buy
248,886
+350
+0.1% +$14.8K 0.02% 425
2022
Q4 		$11.9M Buy
248,536
+144,961
+140% +$5.69M 0.03% 373
2022
Q3 		$2.49M Buy
103,575
+28,665
+38% +$727K 0.01% 712
2022
Q2 		$1.63M Buy
74,910
+39,010
+109% +$903K ﹤0.01% 889
2022
Q1 		$867K Buy
35,900
+34,480
+2,428% +$753K ﹤0.01% 1287
2021
Q4 		$34K Buy
+1,420
New +$33K ﹤0.01% 2162
2021
Q2 		– Sell
-20,873
Closed -$412K – 1847
2021
Q1 		$412K Hold
20,873
– – ﹤0.01% 1626
2020
Q4 		$555K Buy
+20,873
New +$776K ﹤0.01% 1583

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ensign Peak Advisors's PCVX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Vaxcyte (PCVX) stake by 14% in Q2 2026, selling an estimated $3.49M and leaving 381,686 shares worth $22.2M. The position accounts for 0.04% of the portfolio, ranked #301.

Ensign Peak Advisors first reported a position in PCVX in Q4 2020 and has held it in 21 quarters since. The position peaked at $62.5M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Ensign Peak Advisors held 381,686 shares of Vaxcyte worth $22.2M as of Q2 2026.
  • Ensign Peak Advisors sold 64,217 Vaxcyte shares in Q2 2026, an estimated $3.49M.
  • Vaxcyte made up 0.04% of Ensign Peak Advisors's portfolio in Q2 2026, its #301 holding.
  • Ensign Peak Advisors first reported a position in Vaxcyte in Q4 2020 and has held it in 21 quarters since.
  • Ensign Peak Advisors's Vaxcyte position peaked at $62.5M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.